Mosaic Stock Earnings Reports

Key points for investors:

- Market environment: Global fertilizer markets are highly disrupted by geopolitical events in the Persian Gulf and Black Sea, tightening raw-material flows (notably sulfur and ammonia) and driving volatility in phosphate supply and margins. Demand patterns are divergent by region: weaker farm affordability in the Americas and Brazil, but stronger demand in parts of Asia (e.g., India).

- Operational response: Mosaic is taking temporary production curtailments to preserve margin and working capital — partially reducing production at Bartow and Louisiana and scaling back some fertilizer production in Brazil. These actions are reversible and intended to conserve higher-cost sulfur inventories for when margins improve.

- Q1 performance: Phosphate sales were strong at 1.9 million tonnes (highest quarterly phosphate sales in five years). Three of four U.S. phosphate facilities ran at target phosphoric acid rates; New Wales turnaround completed in March. Potash remains strong with balanced fundamentals and robust demand (Canpotex committed through June).

- Raw-material cost outlook: Management provided near-term guidance for phosphate segment realized costs: Q2 sulfur roughly $540/tonne and ammonia roughly $610/tonne. Rising marginal sulfur/ammonia costs are compressing stripping margins and driving curtailments.

- Financial / capital allocation: CapEx guidance for 2026 reduced by $250 million to $1.25 billion. Workforce reduction initiated expected to yield $50 million annualized savings (with $15 million realized in 2026), on top of prior $100 million value-capture program. Mosaic sold noncore assets (three mines; Carlsbad) and idled underperforming sites (Araxa, Patrocinio) to reallocate capital.

- Working capital & cash flow: Finished-goods phosphate inventory declined by roughly $120 million in Q1. Management continues to target a $300–$500 million working-capital release but notes opposing forces: higher raw-material prices (push against release) vs. curtailments (accelerate release). Free cash flow remains a top priority.

- Growth/longer-term projects: Mosaic Biosciences continues to scale (8–10 new products planned in 2026; revenues expected to double again). Company pursuing long-term rare-earth recovery opportunities from phosphogypsum in Brazil and evaluating similar options in the U.S.

- Risk/visibility: Visibility into the back half of 2026 is limited. Management emphasized that the primary variable they are monitoring is sulfur availability and price (and the Strait of Hormuz), and that further curtailments or reaccelerations depend on how raw-material flows and global stripping margins evolve.